Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

The shrinking ranks of "Dividend Knight" contenders. Healthcare stocks with hard times but high yields. What investors should ...

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

Novo Nordisk is facing a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to increased competition and potential US tariffs.

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

President Trump’s latest tariff threat has targeted a sector that’s already hobbled.

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...